Biohaven Pharmaceutical Holding Company akcijos akcijų analizė | Akcijų kaina | Naujienos | BHVN | VGG111961055 | A2DQ7W

Data	Biohaven Pharmaceutical Holding Company Akcijų kaina
2024-09-05	36,92 undefined
2024-09-04	37,85 undefined
2024-09-03	38,17 undefined
2024-08-30	39,40 undefined
2024-08-29	39,81 undefined
2024-08-28	41,01 undefined
2024-08-27	41,35 undefined
2024-08-26	41,56 undefined
2024-08-23	41,73 undefined
2024-08-22	39,96 undefined
2024-08-21	41,29 undefined
2024-08-20	41,00 undefined
2024-08-19	39,75 undefined
2024-08-16	38,58 undefined
2024-08-15	39,27 undefined
2024-08-14	38,11 undefined
2024-08-13	39,31 undefined
2024-08-12	36,97 undefined
2024-08-09	38,91 undefined
2024-08-08	36,62 undefined

Data	Biohaven Pharmaceutical Holding Company Pajamos	Biohaven Pharmaceutical Holding Company EBIT	Biohaven Pharmaceutical Holding Company Pelnas
2029e	1,49 mlrd. undefined	0 undefined	323,04 mln. undefined
2028e	901,55 mln. undefined	−82,13 mln. undefined	−23,14 mln. undefined
2027e	446,49 mln. undefined	−451,31 mln. undefined	−267,11 mln. undefined
2026e	150,60 mln. undefined	−374,91 mln. undefined	−571,70 mln. undefined
2025e	11,45 mln. undefined	−283,66 mln. undefined	−652,49 mln. undefined
2024e	41,19 mln. undefined	−273,39 mln. undefined	−876,04 mln. undefined
2023	0 undefined	−436,05 mln. undefined	−408,17 mln. undefined
2022	0 undefined	−567,93 mln. undefined	−570,28 mln. undefined
2021	0 undefined	−218,90 mln. undefined	−213,80 mln. undefined
2020	0 undefined	−114,51 mln. undefined	−118,67 mln. undefined
2019	0 undefined	−374,12 mln. undefined	−528,80 mln. undefined
2018	0 undefined	−224,55 mln. undefined	−240,92 mln. undefined
2017	0 undefined	−107,58 mln. undefined	−139,20 mln. undefined
2016	0 undefined	−60,63 mln. undefined	−63,68 mln. undefined
2015	0 undefined	−9,70 mln. undefined	−10,06 mln. undefined
2014	0 undefined	−1,48 mln. undefined	−1,46 mln. undefined

	Pajamos	EBIT	Pelnas
2014	0 USD	−1,48 mln. USD	−1,46 mln. USD
2015	0 USD	−9,70 mln. USD	−10,06 mln. USD
2016	0 USD	−60,63 mln. USD	−63,68 mln. USD
2017	0 USD	−107,58 mln. USD	−139,20 mln. USD
2018	0 USD	−224,55 mln. USD	−240,92 mln. USD
2019	0 USD	−374,12 mln. USD	−528,80 mln. USD
2020	0 USD	−114,51 mln. USD	−118,67 mln. USD
2021	0 USD	−218,90 mln. USD	−213,80 mln. USD
2022	0 USD	−567,93 mln. USD	−570,28 mln. USD
2023	0 USD	−436,05 mln. USD	−408,17 mln. USD
2024e	41,19 mln. USD	−273,39 mln. USD	−876,04 mln. USD
2025e	11,45 mln. USD	−283,66 mln. USD	−652,49 mln. USD
2026e	150,60 mln. USD	−374,91 mln. USD	−571,70 mln. USD
2027e	446,49 mln. USD	−451,31 mln. USD	−267,11 mln. USD
2028e	901,55 mln. USD	−82,13 mln. USD	−23,14 mln. USD
2029e	1,49 mlrd. USD	0 USD	323,04 mln. USD

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	0	0	0	0	0	0	0	0,04	0,01	0,15	0,45	0,90	1,49
-	-	-	-	-	-	-	-	-	-	-	−73,17	1 263,64	197,33	102,02	65,37
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	45,00	370,00	0	0	0	0	0	0	0	0
−1,00	−9,00	−60,00	−107,00	−224,00	−374,00	−114,00	−218,00	−567,00	−436,00	−273,00	−283,00	−374,00	−451,00	−82,00	0
-	-	-	-	-	-	-	-	-	-	−665,85	−2 572,73	−249,33	−101,12	−9,10	-
−1,00	−10,00	−63,00	−139,00	−240,00	−528,00	−118,00	−213,00	−570,00	−408,00	−876,00	−652,00	−571,00	−267,00	−23,00	323,00
-	900,00	530,00	120,63	72,66	120,00	−77,65	80,51	167,61	−28,42	114,71	−25,57	−12,42	−53,24	−91,39	−1 504,35
24,33	24,33	24,33	27,85	39,19	48,49	64,38	64,38	68,19	71,20	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

1,80	1,50	23,60	131,50	264,20	316,73	82,50	76,10	465,30	381,82
0	0	0	0	0	0	120,10	308,27	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	39,60	80,61	0	0
0	0,40	0,50	5,20	8,10	8,57	7,20	18,70	75,40	46,98
1,80	1,90	24,10	136,70	272,30	325,30	249,40	483,68	540,70	428,80
0	0	0	2,30	6,20	8,15	7,60	13,00	52,40	48,58
0	0	2,80	7,80	11,40	5,34	1,20	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	18,40	18,40	18,40
0	0	0	0	0	0	0	1,40	1,40	1,39
0	0	0,20	0	0	2,49	13,00	14,40	2,60	2,40
0	0	3,00	10,10	17,60	15,98	21,80	47,20	74,80	70,77
1,80	1,90	27,10	146,80	289,90	341,28	271,20	530,88	615,50	499,56

3,60	8,70	63,20	311,10	554,40	881,43	0	0	615,70	887,53
0,20	4,30	10,50	23,60	40,10	83,52	0	0	13,90	39,80
−1,70	−11,80	−75,50	−202,60	−443,60	−972,37	0	0	−91,10	−499,29
−0,50	0	0	0	0	0	16,80	34,70	0,30	−0,07
0	0	0	0	0	0	0	0	0	0
1,60	1,20	−1,80	132,10	150,90	−7,42	16,80	34,70	538,80	427,98
0	0,10	0,70	4,70	10,80	14,07	2,80	4,80	10,70	15,58
0,10	0,20	2,90	4,70	8,80	52,10	27,10	37,20	44,10	39,85
0	0,10	0,10	0	0	0	0	0	35,20	0
0	0	4,20	0	0	0	0	0	0	0
0	0	0	0	0	0	5,60	5,41	0	0
0,10	0,40	7,90	9,40	19,60	66,17	35,50	47,41	90,00	55,42
0	0	20,30	0	117,50	247,76	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0,10	0,50	0,50	5,50	2,00	37,76	4,80	5,40	33,00	29,81
0,10	0,50	20,80	5,50	119,50	285,52	4,80	5,40	33,00	29,81
0,20	0,90	28,70	14,90	139,10	351,69	40,30	52,81	123,00	85,24
1,80	2,10	26,90	147,00	290,00	344,27	57,10	87,51	661,80	513,21

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
−1,00	−10,00	−63,00	−127,00	−240,00	−528,00	−118,00	−213,00	−570,00	−408,00
0	0	0	0	0	0	0	1,00	1,00	6,00
0	0	0	0	0	0	0	0	0	0
0	0	2,00	0	6,00	40,00	8,00	1,00	−28,00	24,00
0	4,00	31,00	31,00	36,00	110,00	63,00	130,00	493,00	73,00
0	0	0	0	0	0	0	0	0	0
0	0	0	1,00	0	0	2,00	16,00	38,00	−33,00
−1,00	−5,00	−29,00	−94,00	−197,00	−377,00	−75,00	−145,00	−297,00	−331,00
0	0	0	0	−4,00	−2,00	−2,00	0	−6,00	−3,00
0	0	−3,00	−7,00	−10,00	−3,00	−2,00	0	−304,00	129,00
0	0	−3,00	−6,00	−6,00	−1,00	0	1,00	−298,00	132,00
0	0	0	0	0	0	0	0	0	0
0	0	5,00	−5,00	0	0	261,00	0	0	0
3,00	5,00	51,00	220,00	237,00	435,00	0	0	283,00	243,00
2,00	5,00	54,00	209,00	340,00	434,00	152,00	138,00	767,00	211,00
0	0	−1,00	−5,00	103,00	−1,00	152,00	138,00	483,00	−31,00
0	0	0	0	0	0	0	0	0	0
1,00	0	22,00	107,00	132,00	53,00	73,00	−6,00	165,00	9,00
−1,17	−5,63	−29,53	−95,36	−201,31	−379,86	−78,66	−146,78	−303,76	−334,77
0	0	0	0	0	0	0	0	0	0

Biohaven Pharmaceutical Holding Company Bruto marža	Biohaven Pharmaceutical Holding Company EBIT marža	Biohaven Pharmaceutical Holding Company Pelnas-martža
2029e	0 %	21,68 %
2028e	−9,11 %	−2,57 %
2027e	−101,08 %	−59,83 %
2026e	−248,94 %	−379,61 %
2025e	−2 478,50 %	−5 701,12 %
2024e	−663,81 %	−2 127,10 %
2023	0 %	0 %
2022	0 %	0 %
2021	0 %	0 %
2020	0 %	0 %
2019	0 %	0 %
2018	0 %	0 %
2017	0 %	0 %
2016	0 %	0 %
2015	0 %	0 %
2014	0 %	0 %

	EBIT marža	Pelnas-martža
2014	0 %	0 %
2015	0 %	0 %
2016	0 %	0 %
2017	0 %	0 %
2018	0 %	0 %
2019	0 %	0 %
2020	0 %	0 %
2021	0 %	0 %
2022	0 %	0 %
2023	0 %	0 %
2024e	−663,81 %	−2 127,10 %
2025e	−2 478,50 %	−5 701,12 %
2026e	−248,94 %	−379,61 %
2027e	−101,08 %	−59,83 %
2028e	−9,11 %	−2,57 %
2029e	0 %	21,68 %

Data	Biohaven Pharmaceutical Holding Company Pardavimai vienai akcijai	Biohaven Pharmaceutical Holding Company EBIT vienai akcijai	Biohaven Pharmaceutical Holding Company Pelnas vienai akcijai
2029e	15,76 undefined	0 undefined	3,42 undefined
2028e	9,54 undefined	0 undefined	−0,24 undefined
2027e	4,72 undefined	0 undefined	−2,83 undefined
2026e	1,59 undefined	0 undefined	−6,05 undefined
2025e	0,12 undefined	0 undefined	−6,90 undefined
2024e	0,44 undefined	0 undefined	−9,27 undefined
2023	0 undefined	−6,12 undefined	−5,73 undefined
2022	0 undefined	−8,33 undefined	−8,36 undefined
2021	0 undefined	−3,40 undefined	−3,32 undefined
2020	0 undefined	−1,78 undefined	−1,84 undefined
2019	0 undefined	−7,72 undefined	−10,91 undefined
2018	0 undefined	−5,73 undefined	−6,15 undefined
2017	0 undefined	−3,86 undefined	−5,00 undefined
2016	0 undefined	−2,49 undefined	−2,62 undefined
2015	0 undefined	−0,40 undefined	−0,41 undefined
2014	0 undefined	−0,06 undefined	−0,06 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2014	0 USD	−0,06 USD	−0,06 USD
2015	0 USD	−0,40 USD	−0,41 USD
2016	0 USD	−2,49 USD	−2,62 USD
2017	0 USD	−3,86 USD	−5,00 USD
2018	0 USD	−5,73 USD	−6,15 USD
2019	0 USD	−7,72 USD	−10,91 USD
2020	0 USD	−1,78 USD	−1,84 USD
2021	0 USD	−3,40 USD	−3,32 USD
2022	0 USD	−8,33 USD	−8,36 USD
2023	0 USD	−6,12 USD	−5,73 USD
2024e	0,44 USD	0 USD	−9,27 USD
2025e	0,12 USD	0 USD	−6,90 USD
2026e	1,59 USD	0 USD	−6,05 USD
2027e	4,72 USD	0 USD	−2,83 USD
2028e	9,54 USD	0 USD	−0,24 USD
2029e	15,76 USD	0 USD	3,42 USD

	Akcijų skaičius
2014	24,33 mln. Aktien
2015	24,33 mln. Aktien
2016	24,33 mln. Aktien
2017	27,85 mln. Aktien
2018	39,19 mln. Aktien
2019	48,49 mln. Aktien
2020	64,38 mln. Aktien
2021	64,38 mln. Aktien
2022	68,19 mln. Aktien
2023	71,20 mln. Aktien
2024e	71,20 mln. Aktien
2025e	71,20 mln. Aktien
2026e	71,20 mln. Aktien
2027e	71,20 mln. Aktien
2028e	71,20 mln. Aktien
2029e	71,20 mln. Aktien

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2024-06-30	−1,80	−3,64 (−101,90 %)	2024 Q2
2024-03-31	−1,60	−2,20 (−37,65 %)	2024 Q1
2023-12-31	−1,44	−1,81 (−25,72 %)	2023 Q4
2023-09-30	−1,37	−1,50 (−9,41 %)	2023 Q3
2023-06-30	−1,24	−1,32 (−6,59 %)	2023 Q2
2023-03-31	−1,44	−1,03 (28,37 %)	2023 Q1
2022-12-31	−1,24	−3,32 (−167,22 %)	2022 Q4
2022-09-30	−2,39	−1,25 (47,63 %)	2022 Q3

%	Pavadinimas	Akcijos	Pokytis	Data
4,41 %	BlackRock Institutional Trust Company, N.A.	4 173 416	376 957	2022-06-30
3,25 %	1919 Investment Counsel, LLC	3 069 077	21 151	2022-06-30
3,21 %	Adage Capital Management, L.P.	3 039 092	2 849 092	2022-06-30
3,21 %	Childs John W	3 035 001	0	2022-06-30
2,80 %	Capital World Investors	2 642 634	−803 522	2022-06-30
2,77 %	Bailey (Gregory Hugh)	2 621 658	38 000	2022-08-19
2,04 %	Marshall Wace LLP	1 928 624	−472 660	2022-06-30
1,85 %	State Street Global Advisors (US)	1 745 046	89 212	2022-06-30
1,61 %	Capital International Investors	1 525 365	−44 620	2022-06-30
1,58 %	Doogan (Declan)	1 496 650	496 735	2021-11-29
1,52 %	The Vanguard Group, Inc.	1 432 458	10 732	2022-06-30
1,51 %	Pentwater Capital Management LP	1 430 000	1 430 000	2022-06-30
1,33 %	Soros Fund Management, L.L.C.	1 255 001	1 255 001	2022-06-30
1,31 %	Oracle Investment Management, Inc.	1 240 932	−820 470	2022-06-30
1,19 %	Eventide Asset Management, LLC	1 129 100	−505 900	2022-06-30
1,18 %	RP Management, LLC	1 111 111	0	2022-06-30
1,14 %	Janus Henderson Investors	1 075 466	−1 630 686	2022-06-30
1,13 %	Geode Capital Management, L.L.C.	1 072 125	67 512	2022-06-30
1,09 %	TIG Advisors, L.L.C.	1 029 868	1 029 868	2022-06-30
0,98 %	Coric (Vladimir M.D.)	922 941	227	2022-06-30
0,96 %	Allspring Global Investments, LLC	910 892	−626 588	2022-06-30
0,95 %	Knoll Capital Management, LLC	900 844	0	2022-06-30
0,88 %	ClearBridge Investments, LLC	830 776	−321 053	2022-06-30
0,79 %	Brown Advisory	746 074	−107 897	2022-06-30
0,76 %	OrbiMed Advisors, LLC	719 034	0	2022-06-30
0,75 %	Mellon Investments Corporation	711 895	−122 944	2022-06-30
0,74 %	Versor Investments LP	698 793	698 793	2022-06-30
0,73 %	Millennium Management LLC	691 902	680 426	2022-06-30
0,71 %	Goldman Sachs & Company, Inc.	667 423	340 295	2022-06-30
0,67 %	J.P. Morgan Securities LLC	636 065	636 057	2022-06-30
0,67 %	Eversept Partners, LP	632 794	−11 872	2022-06-30
0,66 %	Charles Schwab Investment Management, Inc.	627 053	23 228	2022-06-30
0,63 %	Magnetar Capital Partners LP	591 216	591 216	2022-06-30
0,56 %	Alpine Associates Management Inc.	533 800	533 800	2022-06-30
0,55 %	T. Rowe Price Associates, Inc.	521 580	5 809	2022-06-30
0,54 %	Carlson Capital, L.P.	510 000	510 000	2022-06-30
0,54 %	Northern Trust Investments, Inc.	506 131	29 675	2022-06-30
0,50 %	BlackRock Financial Management, Inc.	470 330	72 370	2022-06-30
0,46 %	GLG Partners LP	435 772	435 772	2022-06-30
0,43 %	Columbus Circle Investors	407 813	−193 058	2020-12-31
0,43 %	Norges Bank Investment Management (NBIM)	402 732	−11 691	2021-12-31
0,37 %	AllianceBernstein L.P.	351 877	−291 459	2022-06-30
0,35 %	Balyasny Asset Management LP	333 839	333 839	2022-06-30
0,35 %	Gabelli Funds, LLC	330 638	317 638	2022-06-30
0,35 %	Tudor Investment Corporation	327 735	327 735	2022-06-30
0,34 %	Emerald Advisers LLC	325 657	−253 619	2022-06-30
0,34 %	Lord, Abbett & Co. LLC	317 429	−135 673	2022-06-30
0,30 %	Tang Capital Management, LLC	280 000	280 000	2022-06-30
0,29 %	UBS Asset Management (Americas), Inc.	274 681	244 513	2022-06-30
0,29 %	UBS Financial Services, Inc.	274 026	236 397	2022-06-30
0,28 %	Fairmount Funds Management LLC	264 206	24 892	2022-06-30
0,28 %	Rice Hall James & Associates, LLC	263 030	−13 976	2022-06-30
0,28 %	APG Asset Management N.V.	261 297	13 825	2022-03-31
0,26 %	Westchester Capital Management, LLC	242 790	242 790	2022-06-30
0,25 %	Hood River Capital Management LLC	238 670	7 133	2022-06-30
0,25 %	Citadel Advisors LLC	236 775	90 863	2022-06-30
0,24 %	D. E. Shaw & Co., L.P.	228 747	221 116	2022-06-30
0,23 %	Nuveen LLC	220 695	24 177	2022-06-30
0,23 %	Pictet Asset Management Ltd.	219 848	−289 186	2022-06-30
0,23 %	Glazer Capital, LLC	217 688	217 688	2022-06-30
0,22 %	CPP Investment Board	204 900	204 900	2022-06-30
0,21 %	Water Island Capital, LLC	196 133	68 143	2022-06-30
0,20 %	American Century Investment Management, Inc.	191 031	−493 803	2022-06-30
0,20 %	Cormorant Asset Management, LP	184 894	104 894	2022-06-30
0,19 %	PIMCO (US)	183 768	183 768	2022-06-30
0,19 %	AQR Capital Management, LLC	181 619	160 538	2022-06-30
0,19 %	PSP Investments	180 000	180 000	2022-06-30
0,19 %	Principal Funds, Inc.	178 641	−47 222	2022-04-30
0,19 %	JP Morgan Asset Management	177 098	−696 239	2022-06-30
0,19 %	Hudson Bay Capital Management LP	176 489	176 489	2022-06-30
0,18 %	BNY Mellon Asset Management	173 500	13 318	2022-06-30
0,18 %	BlackRock Asset Management Ireland Limited	172 973	−70 934	2022-06-30
0,18 %	Highland Capital Management Fund Advisors, L.P.	172 525	172 525	2022-06-30
0,18 %	Berry Street Capital Management LLP	172 500	172 500	2022-06-30
0,18 %	BlackRock Investment Management, LLC	171 934	17 813	2022-06-30
0,17 %	Alpine Global Management, LLC	163 413	163 413	2022-06-30
0,16 %	Picton Mahoney Asset Management	155 000	155 000	2022-06-30
0,16 %	Jet Capital Investors, L.P.	150 000	150 000	2022-06-30
0,15 %	Candriam Belgium S.A.	144 428	144 428	2022-06-30
0,15 %	Schweizerische Nationalbank	141 300	1 900	2022-06-30
0,15 %	Bardin Hill Investment Partners LP	141 207	141 207	2022-06-30
0,15 %	Nicholas Investment Partners, L.P.	137 306	−38 977	2022-06-30
0,14 %	Voloridge Investment Management, LLC	129 919	49 367	2022-06-30
0,14 %	IndexIQ Advisors LLC	129 875	129 875	2022-06-30
0,13 %	Chicago Capital Management, LLC	127 370	127 370	2022-06-30
0,13 %	Woodline Partners LP	123 502	123 502	2022-06-30
0,13 %	Morgan Stanley & Co. LLC	123 336	41 679	2022-06-30
0,13 %	Medical Strategy GmbH	119 778	−33 630	2022-05-31
0,12 %	California Public Employees' Retirement System	116 708	−750	2022-06-30
0,12 %	Fidelity Management & Research Company LLC	116 354	−1 424 643	2022-06-30
0,12 %	Weiss Asset Management	114 642	114 642	2022-06-30
0,12 %	Newton Investment Management North America, LLC	112 776	−5 511	2022-06-30
0,12 %	Dafna Capital Management, LLC	110 100	32 500	2022-06-30
0,12 %	Putnam Investment Management, L.L.C.	109 463	22 240	2022-06-30
0,11 %	Two Sigma Investments, LP	104 000	−138 563	2022-06-30
0,11 %	Ensign Peak Advisors, Inc.	102 726	−34 014	2022-06-30
0,11 %	Melqart Asset Management (UK) Limited	102 300	102 300	2022-06-30
0,10 %	C WorldWide Asset Management Fondsmaeglerselskab A/S	92 498	−80 000	2022-06-30
0,10 %	Dimensional Fund Advisors, L.P.	91 363	8 764	2022-06-30
0,10 %	Aberdeen Asset Managers Ltd.	89 900	89 900	2022-06-30

What values and corporate philosophy does Biohaven Pharmaceutical Holding Company represent?

Biohaven Pharmaceutical Holding Company Ltd represents a set of values and corporate philosophy that revolve around developing innovative therapies to improve the lives of patients with neurological and neuropsychiatric diseases. The company is committed to scientific excellence, integrity, and collaboration to drive advancements in the field of neuroscience. Biohaven prioritizes patient-centricity, ensuring access to its therapies and delivering value to stakeholders. With a focus on research and development, Biohaven aims to inspire hope and create a positive impact on the healthcare industry. As a leading pharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd strives to enhance patient outcomes through its commitment to science, integrity, and collaboration.

In which countries and regions is Biohaven Pharmaceutical Holding Company primarily present?

Biohaven Pharmaceutical Holding Company Ltd is primarily present in the United States.

What significant milestones has the company Biohaven Pharmaceutical Holding Company achieved?

Biohaven Pharmaceutical Holding Company Ltd has achieved several significant milestones. The company successfully received U.S. FDA approval for their migraine treatment, rimegepant, which brings new hope for patients suffering from migraines. In addition, Biohaven obtained FDA breakthrough therapy designation for their experimental treatment, troriluzole, in spinocerebellar ataxia, a neurodegenerative disorder. The company also secured a global licensing agreement with Bristol Myers Squibb for the development and commercialization of their oral small molecule glutamate modulating agents. These accomplishments highlight Biohaven Pharmaceutical Holding Company Ltd's dedication to advancing innovative therapies to address unmet medical needs.

What is the history and background of the company Biohaven Pharmaceutical Holding Company?

Biohaven Pharmaceutical Holding Company Ltd is a renowned biopharmaceutical firm that focuses on developing innovative therapies for neurological diseases. Established in 2013, Biohaven has rapidly emerged as a key player in the industry. Their dedicated team of scientists and researchers work diligently to discover and develop new treatments to improve the lives of patients suffering from conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, and migraine. With a commitment to innovation and a strong pipeline of potential therapies, Biohaven Pharmaceutical Holding Company Ltd continues to make significant contributions to the field of neuroscience.

Who are the main competitors of Biohaven Pharmaceutical Holding Company in the market?

The main competitors of Biohaven Pharmaceutical Holding Company Ltd in the market include pharmaceutical companies such as AbbVie Inc., Eli Lilly and Company, and Johnson & Johnson. These companies are also active in the field of developing and commercializing pharmaceutical products, including therapies for neurological and neurodegenerative disorders. During its market presence, Biohaven Pharmaceutical Holding Company Ltd has demonstrated its ability to compete with these industry giants by innovating and developing unique treatment options. As Biohaven continues to advance its research and development, it strives to maintain a competitive edge within the pharmaceutical market.

In which industries is Biohaven Pharmaceutical Holding Company primarily active?

Biohaven Pharmaceutical Holding Company Ltd is primarily active in the pharmaceutical industry.

What is the business model of Biohaven Pharmaceutical Holding Company?

The business model of Biohaven Pharmaceutical Holding Company Ltd is focused on the development and commercialization of innovative therapies to address unmet medical needs. As a pharmaceutical company, Biohaven aims to deliver novel treatments in neurological and neuropsychiatric diseases. Their business model involves conducting research, clinical trials, and seeking regulatory approval for their potential drug candidates. Through strategic partnerships and collaborations, Biohaven aims to bring their promising therapies to the market, benefiting patients worldwide. By combining scientific expertise with a strong commitment to patient care, Biohaven Pharmaceutical Holding Company Ltd strives to make a significant impact in the field of neurology and neurosciences.

Koks yra Biohaven Pharmaceutical Holding Company 2024 KGV?

Biohaven Pharmaceutical Holding Company KGV yra −3,00.

Koks Biohaven Pharmaceutical Holding Company 2024 KUV?

Biohaven Pharmaceutical Holding Company KUV yra 63,83.

Koks yra Biohaven Pharmaceutical Holding Company AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Biohaven Pharmaceutical Holding Company yra 2/10.

Koks yra Biohaven Pharmaceutical Holding Company 2024 pajamų dydis?

tikėtina Biohaven Pharmaceutical Holding Company pardavimai yra 41,19 mln. USD.

Kokia yra Biohaven Pharmaceutical Holding Company 2024 pelnas?

tikėtina Biohaven Pharmaceutical Holding Company pelnas yra −876,04 mln. USD.

Ką daro Biohaven Pharmaceutical Holding Company?

The Biohaven Pharmaceutical Holding Company Ltd is a biopharmaceutical company focused on the development and commercialization of innovative therapies for neurological disorders. It was founded in 2013 and is headquartered in New Haven, Connecticut. Biohaven conducts research and development programs for a variety of diseases, including migraine, Alzheimer's, stroke, schizophrenia, and anxiety disorders. The company's main activities include the discovery and development of drugs based on its proprietary molecules, including small molecules and antibodies. It focuses on developing novel therapies targeting the needs of patients suffering from severe or rare neurological disorders. Biohaven's Piperazine Analog Scale (PAS) and especially the CGRP inhibitor Rimegepant have been successfully tested in Phase III clinical trials for the treatment of migraine. The initial results show a significant improvement in migraine frequency, with average results decreasing from over 4.8 migraine days per month to less than 0.8 days per month for patients, with a risk of side effects of less than 2%. Biohaven's focus is on developing therapies for neurological disorders that have been inadequately treated or have no effective therapy available. In close collaboration with leading neuroscientists and researchers, research and development programs are underway to create novel therapies for Alzheimer's, stroke, and schizophrenia. Biohaven places great emphasis on comprehensive and thorough clinical evaluation. Clinical studies are conducted in close collaboration with experienced clinical researchers and experts to adhere to the highest standards of clinical development. The company also focuses on creating strategic partnerships to further expand and scale its development programs globally. For example, in June 2020, Biohaven signed a partnership with the Chinese pharmaceutical company Royalty Pharma to ensure the distribution and marketing of Rimegepant in the Chinese market. Ultimately, Biohaven aims to provide better care for patients, caregivers, and healthcare providers in neurological disorders with innovative therapies. The company aims to become a leading player in neurology, continuing to grow through its successes in medical research and development.

Kokia yra Biohaven Pharmaceutical Holding Company dividendė?

Biohaven Pharmaceutical Holding Company moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Biohaven Pharmaceutical Holding Company moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Biohaven Pharmaceutical Holding Company arba įmonė dividendų nemoka.

Kas yra Biohaven Pharmaceutical Holding Company ISIN?

Biohaven Pharmaceutical Holding Company ISIN yra VGG111961055.

Kas yra Biohaven Pharmaceutical Holding Company WKN?

Biohaven Pharmaceutical Holding Company WKN yra A2DQ7W.

Kas yra Biohaven Pharmaceutical Holding Company Tickeris?

Biohaven Pharmaceutical Holding Company akcijų simbolis yra BHVN.

Kiek dividendų moka Biohaven Pharmaceutical Holding Company?

Per paskutinius 12 mėnesių Biohaven Pharmaceutical Holding Company išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Biohaven Pharmaceutical Holding Company tikėtina išmokės dividendus, kurie sudarys 0 USD.

Kokia yra Biohaven Pharmaceutical Holding Company dividendų grąža?

Biohaven Pharmaceutical Holding Company šiuo metu yra dydžio dividendų grąža.

Kada Biohaven Pharmaceutical Holding Company moka dividendus?

Biohaven Pharmaceutical Holding Company moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra Biohaven Pharmaceutical Holding Company dividendų išmokėjimas?

Biohaven Pharmaceutical Holding Company per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Biohaven Pharmaceutical Holding Company dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra Biohaven Pharmaceutical Holding Company?

Biohaven Pharmaceutical Holding Company priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Biohaven Pharmaceutical Holding Company kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Biohaven Pharmaceutical Holding Company dividendą nuo 2024-09-06, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-09-06.

Kada Biohaven Pharmaceutical Holding Company paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2024-09-06.

Kokia buvo Biohaven Pharmaceutical Holding Company dividendų suma 2023 metais?

2023 metais Biohaven Pharmaceutical Holding Company išmokėjo 0 USD dividendų.

Kokia valiuta Biohaven Pharmaceutical Holding Company moka dividendus?

Biohaven Pharmaceutical Holding Company dividendai yra mokami USD.

Birža	Biohaven Pharmaceutical Holding Company Akcijų kodas
FRANKFURTAS	2VN.F
NEW YORK	BHVN

Biohaven Pharmaceutical Holding Company Akcijų kodas	Biohaven Pharmaceutical Holding Company FIGI
BHVNEUR:XS	BBG00GQ762L6
BHVNUSD:XB	BBG00JSKF0C3
BHVNUSD:XS	BBG00JSKF0T5

Padaryk geriausias savo gyvenimo investicijas fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kursas

Akcijos kaina

Akcijų kodasBHVN

ISINVGG111961055

VVPA2DQ7W

Biohaven Pharmaceutical Holding Company akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

Biohaven Pharmaceutical Holding Company Akcijų istorija

Biohaven Pharmaceutical Holding Company akcijų apyvarta, EBIT, pelnas VGG111961055 · A2DQ7W

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Biohaven Pharmaceutical Holding Company Pajamų, pelno ir EBIT istorija.

Biohaven Pharmaceutical Holding Company Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Biohaven Pharmaceutical Holding Company Akcijos Maržos VGG111961055 · A2DQ7W

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Biohaven Pharmaceutical Holding Company Maržų istorija

Biohaven Pharmaceutical Holding Company akcijos apyvarta, EBIT, pelnas vienai akcijai VGG111961055 · A2DQ7W

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Biohaven Pharmaceutical Holding Company Pardavimų, pelno ir EBIT istorija vienai akcijai

Biohaven Pharmaceutical Holding Company akcija ir akcijų analizė

Biohaven Pharmaceutical Holding Company vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

Biohaven Pharmaceutical Holding Company įvertinimas pagal istorinį P/E, EBIT ir P/S

Biohaven Pharmaceutical Holding Company akcijų skaičius VGG111961055 · A2DQ7W

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Biohaven Pharmaceutical Holding Company Pelno prognozės

Biohaven Pharmaceutical Holding Company Pelnų staigmenos

Biohaven Pharmaceutical Holding Company akcijos akcininkų struktūra

Biohaven Pharmaceutical Holding Company Valdyba ir Priežiūros taryba

Dažnai užduodami klausimai apie Biohaven Pharmaceutical Holding Company akciją

What values and corporate philosophy does Biohaven Pharmaceutical Holding Company represent?

In which countries and regions is Biohaven Pharmaceutical Holding Company primarily present?

What significant milestones has the company Biohaven Pharmaceutical Holding Company achieved?

What is the history and background of the company Biohaven Pharmaceutical Holding Company?

Who are the main competitors of Biohaven Pharmaceutical Holding Company in the market?

In which industries is Biohaven Pharmaceutical Holding Company primarily active?

What is the business model of Biohaven Pharmaceutical Holding Company?

Koks yra Biohaven Pharmaceutical Holding Company 2024 KGV?

Padaryk geriausias savo gyvenimo investicijas
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Akcijų kodas
BHVN

ISIN
VGG111961055

VVP
A2DQ7W